Our pipeline is composed of IP protected, first-in-class potential assets of novel medicines for significant unmet need, developed via in-house R&D and partnerships through in-license and collaboration with global pharmaceutical and biotech companies. We focus on neurodegenerative and neurological injury disorders by enhancing neuroprotection/repair and controlling neuroinflammation.

Asset Indication Discovery Preclinical IND Phase I Phase II
FB1006 ALS (IIT)
FB-1071 ALS
FB1001 Glaucoma
FB1003 Chronic pain
FB1002 ALS
FB1005 Stroke
FB1007 AD
FB1008 AD
FB1010 AD